06

  • Cell-based therapy for solid tumors

    The FDA recently approved the first cell-based therapy — widely used in treating blood cancers — for solid tumors. Stanford Medicine treated the first patient with advanced melanoma.

  • Stanford Medicine magazine on psychiatry

    The new issue of Stanford Medicine magazine reports on emerging research and innovative treatments to improve mental health.

  • Biochemist Lubert Stryer dies at 86

    Stryer made fundamental discoveries in fluorescence spectroscopy and vision, established structural biology at Stanford, and uplifted young scientists.

  • Shedding light on exercise’s effects

    A Stanford Medicine-led effort to learn more about exercise’s molecular effects paints the broadest picture yet of why, in the health arena, sweat is king.

  • Studying neurodevelopmental disorders

    Stanford Medicine research on Timothy syndrome — which predisposes newborns to autism and epilepsy — may extend well beyond the rare genetic disorder to schizophrenia and other conditions.

  • Chuck Chan dies at 48

    The Stanford Medicine researcher was known for his groundbreaking work and his generous spirit as a mentor and colleague.

  • New epilepsy target

    Researchers find that a little-understood part of the brain appears to be involved in starting seizures and keeping them going.

  • Former medical school dean dies

    David Korn devoted nearly 30 years to Stanford Medicine as chair of pathology and dean of the medical school, overseeing the rise to national prominence amid tumultuous and historic change.

  • AI models help clinician communication

    A new artificial intelligence model helps physicians and nurses work together at Stanford Hospital to boost patient care.

  • Elizabeth Mellins dies

    Mellins, who studied autoimmune disease and co-founded a large pediatric rheumatology research network, was a tireless mentor and advocate for her field.


2024 ISSUE 1

Psychiatry’s new frontiers